Faculty profile

Joseph Brandwein

Back to faculty

ProfessorMedicine DeptUniversity of Alberta

Joseph Brandwein

Professor

Medicine Dept

Faculty of Medicine & Dentistry

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
20 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

680

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Alberta profile.

Latest papers

Controversies in the Management of AML in Older Patients: A Canadian Perspective
Current Oncology · 2026
Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus
Current Oncology · 2026 · senior author
Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias
Blood advances · 2026

All 40 publications

Latest funding

Early discontinuation of antibiotics for unexplained febrile neutropenia: a pilot randomized controlled trial- EASE ANTIBIOTICS pilot trial
CIHR · 2023 · Co-investigator
$512,551
Synthetic Biomaterials to Package and Deliver siRNA Nanoparticles in order to Curb Uncontrolled Growth of Leukemic Cells
CIHR · 2020 · Co-investigator
$757,350
siRNA Therapy for Leukemia: Synthetic Biomaterials to Deliver siRNA and Curb Uncontrolled Growth of Leukemic Cells
CIHR · 2015 · Co-investigator
$597,400

All 3 grants and awards

40 publications.

Controversies in the Management of AML in Older Patients: A Canadian Perspective

Schuh AC, Brandwein J, Elsawy M, Sanford D, Leber B

Current Oncology20261 citationsOpen Access

DOI: 10.3390/curroncol33070431

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus

Schuh AC, Chornenki N, Elemary MA, Elsawy M, Houston BL, Leber B, Mozessohn L, Sabloff M, Salter B, Sanford D

Current Oncology2026Senior authorOpen Access

DOI: 10.3390/curroncol33070429

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM

Blood advances2026Open Access

DOI: 10.1182/bloodadvances.2025018117

Proposed Modifications to Prognostic Classification of AML Patients Treated With Intensive Chemotherapy Based on Recent Real-World Data.

Brandwein J, Page D, Liew E, Croden J, Wang P

Clinical lymphoma, myeloma & leukemia2026First author

DOI: 10.1016/j.clml.2025.10.027 PMID: 41274823

Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia.

Brandwein J, Szkotak A, Page D, Wang P

Leukemia research2026First author

DOI: 10.1016/j.leukres.2026.108206 PMID: 41880981

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM

The Lancet. Haematology20257 citations

DOI: 10.1016/s2352-3026(25)00254-6 PMID: 41075807

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model.

Yotsomnuk P, Rajendran AP, Sundaram DNM, Morales LC, Kucharski C, Nasrullah M, Skolpap W, Jiang X, Gibson SB, Brandwein J, Uludağ H

Biomolecules20257 citationsOpen Access

DOI: 10.3390/biom15010115 PMID: 39858509

Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells.

Gamma JM, Liu Q, Beauchamp E, Iyer A, Yap MC, Zak Z, Ekstrom C, Pain R, Kostiuk MA, Mackey JR, Brandwein J, Wang JCY, Berthiaume LG

Molecular cancer therapeutics20257 citationsOpen Access

DOI: 10.1158/1535-7163.mct-24-0307 PMID: 39382188

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery.

Nasrullah M, Kc R, Rajendran AP, Dezfouli SA, Kucharski C, Jiang X, Gibson SB, Brandwein J, Heidenreich O, Uludağ H

Advanced healthcare materials20252 citationsOpen Access

DOI: 10.1002/adhm.202502019 PMID: 40685918

Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation.

Pituskin E, Foulkes S, Skow RJ, McMurtry T, Kruger C, Bates JE, Lamoureux D, Brandwein J, Lieuw E, Wu C, Zhu N, Wang P, Sawler D, Taparia M, Hamilton M, Comfort-Riddle T, Meyer T, Gyenes GT, Paterson I, Prado CM, Haykowsky MJ, Greiner JG, McNeely ML, Tandon P, Thompson RB

BMC cancer20251 citationsOpen Access

DOI: 10.1186/s12885-025-13502-8 PMID: 39875816

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Joseph Brandwein

Research

Latest papers

Latest funding

Controversies in the Management of AML in Older Patients: A Canadian Perspective

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Proposed Modifications to Prognostic Classification of AML Patients Treated With Intensive Chemotherapy Based on Recent Real-World Data.

Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia.

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model.

Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells.

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery.

Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation.

Early discontinuation of antibiotics for unexplained febrile neutropenia: a pilot randomized controlled trial- EASE ANTIBIOTICS pilot trial

Synthetic Biomaterials to Package and Deliver siRNA Nanoparticles in order to Curb Uncontrolled Growth of Leukemic Cells

siRNA Therapy for Leukemia: Synthetic Biomaterials to Deliver siRNA and Curb Uncontrolled Growth of Leukemic Cells

Frequent collaborators

Hasan Uludag

Xiaoyan Jiang

Cynthia Wu

Sunita Ghosh

Mark Minden

Aaron Schimmer

Faisal Khan

Raymond Lai

Bruce Ritchie

Mohammad Refaei

Spencer Gibson

Brian Leber

Abi Vijenthira

Matthew Cheung

Vikas Gupta

Anca Prica

Jennifer Croden

Dawn Maze

Jill Dudebout

Sita Bhella

Jean Wang

Lambert Busque

Margaret McNeely

Shokrollah Elahi

Mitchell Sabloff

Donna Reece

Puneeta Tandon

Carla Prado

George Tomlinson

Richard Leigh

Steven Chan

Annette Hay

Edith Pituskin